Integrative Cancer Therapies · 2012 · 126 citations · 25 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyChemotherapyAdverse Effects Of ChemotherapyBreast Cancer PharmacotherapyOncology PharmacologySupportive Care In CancerAnticancer ActivityBreast Cancer ChemotherapyChemotherapy-induced FatigueControl Group DesignFatigue ReliefPatient-reported Symptom ScalesTraditional Herbal MedicineWell-being
UNLABELLED: Hypothesis. Withania somnifera is an herb with antioxidant, anti-inflammatory, anticancer, antistress, and adaptogenic properties. Previous studies have shown its antistress effects in animals. Traditional Indian medicine has used it for centuries to alleviate fatigue and improve general well-being. METHODS: This is an open-label prospective nonrandomized comparative trial on 100 patients with breast cancer in all stages undergoing either a combination of chemotherapy with oral Withania somnifera or chemotherapy alone. The chemotherapy regimens were either taxotere, adriamycin, and cyclophosphamide or 5-fluorouracil, epirubicin, and cyclophosphamide. Withania somnifera root extract was administered to patients in the study group at a dose of 2 g every 8 hours, throughout the course of chemotherapy. The quality-of-life and fatigue scores were evaluated before, during, and on the last cycles of chemotherapy using the EORTC QLQ-C30 (Version 3), Piper Fatigue Scale (PFS), and Schwartz Cancer Fatigue Scale (SCFS-6). RESULTS: The median age distributions in the study and control arm were 51 years (range = 36-70) and 50.5 years (range = 32-71), respectively. The majority (77%) of patients had stage II and III disease. Patients in the control arm experienced statistically significant higher estimated marginal means of fatigue score compared with the study group (P < .001 PFS, P < .003 SCFS-6). Furthermore, various symptom scales of the EORTC QLQ-C30 were statistically significant in 7 out of 18 symptoms in the intervention group compared with the control group (P < .001). The 24-month overall survival for all stages in study and control group patients were 72% versus 56%, respectively; however, the result was not significant (P = .176), at a median follow-up duration of 26 months. CONCLUSIONS: Withania somnifera has potential against cancer-related fatigue, in addition to improving the quality of life. However, further study with a larger sample size in a randomized trial is warranted to validate our findings.
25
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer.
Barbara F. Piper, Suzanne L. Dibble, M. Dodd et al. · PubMed · 1998 · 837 citations
Pharmacy, Oncology, Psychology +17
Reinhard Schliebs, André Liebmann, S. K. Bhattacharya et al. · Neurochemistry International · 1997 · 218 citations